This report aims to provide a comprehensive presentation of the global market for Hemoglobinopathies Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemoglobinopathies Drugs. This report contains market size and forecasts of Hemoglobinopathies Drugs in global, including the following market information:
Global Hemoglobinopathies Drugs Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Hemoglobinopathies Drugs Market Sales, 2018-2023, 2024-2032, (K Pcs)
Global top five Hemoglobinopathies Drugs companies in 2022 (%)
The global Hemoglobinopathies Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Thalassemia Therapy Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hemoglobinopathies Drugs include Gamida Cell, Alnylam Pharmaceuticals, Biogen Idec, Sangamo BioSciences Inc., Genetix Pharmaceuticals/Bluebird Bio, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics and Emmaus Life Sciences, Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hemoglobinopathies Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hemoglobinopathies Drugs Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Pcs)
Global Hemoglobinopathies Drugs Market Segment Percentages, by Type, 2022 (%)
Thalassemia Therapy
Sickle Cell Disease(SCD) Therapy
Other Therapy
Global Hemoglobinopathies Drugs Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Pcs)
Global Hemoglobinopathies Drugs Market Segment Percentages, by Application, 2022 (%)
Alpha Thalassemia
Beta thalassemia
Sickle Cell Disease
Hb Variants Diseases
Global Hemoglobinopathies Drugs Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Pcs)
Global Hemoglobinopathies Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hemoglobinopathies Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Hemoglobinopathies Drugs revenues share in global market, 2022 (%)
Key companies Hemoglobinopathies Drugs sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Hemoglobinopathies Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gamida Cell
Alnylam Pharmaceuticals
Biogen Idec
Sangamo BioSciences Inc.
Genetix Pharmaceuticals/Bluebird Bio
Global Blood Therapeutics Inc.
Pfizer Inc.
Mast Therapeutics
Emmaus Life Sciences, Inc.
Prolong Pharmaceuticals
Celgene Corporation
HemaQuest Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hemoglobinopathies Drugs, market overview.
Chapter 2: Global Hemoglobinopathies Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Hemoglobinopathies Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hemoglobinopathies Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Hemoglobinopathies Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Hemoglobinopathies Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hemoglobinopathies Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hemoglobinopathies Drugs Overall Market Size
2.1 Global Hemoglobinopathies Drugs Market Size: 2022 VS 2030
2.2 Global Hemoglobinopathies Drugs Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Hemoglobinopathies Drugs Sales: 2018-2030
3 Company Landscape
3.1 Top Hemoglobinopathies Drugs Players in Global Market
3.2 Top Global Hemoglobinopathies Drugs Companies Ranked by Revenue
3.3 Global Hemoglobinopathies Drugs Revenue by Companies
3.4 Global Hemoglobinopathies Drugs Sales by Companies
3.5 Global Hemoglobinopathies Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Hemoglobinopathies Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Hemoglobinopathies Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Hemoglobinopathies Drugs Players in Global Market
3.8.1 List of Global Tier 1 Hemoglobinopathies Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Hemoglobinopathies Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Hemoglobinopathies Drugs Market Size Markets, 2022 & 2030
4.1.2 Thalassemia Therapy
4.1.3 Sickle Cell Disease(SCD) Therapy
4.1.4 Other Therapy
4.2 By Type - Global Hemoglobinopathies Drugs Revenue & Forecasts
4.2.1 By Type - Global Hemoglobinopathies Drugs Revenue, 2018-2023
4.2.2 By Type - Global Hemoglobinopathies Drugs Revenue, 2024-2030
4.2.3 By Type - Global Hemoglobinopathies Drugs Revenue Market Share, 2018-2030
4.3 By Type - Global Hemoglobinopathies Drugs Sales & Forecasts
4.3.1 By Type - Global Hemoglobinopathies Drugs Sales, 2018-2023
4.3.2 By Type - Global Hemoglobinopathies Drugs Sales, 2024-2030
4.3.3 By Type - Global Hemoglobinopathies Drugs Sales Market Share, 2018-2030
4.4 By Type - Global Hemoglobinopathies Drugs Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hemoglobinopathies Drugs Market Size, 2022 & 2030
5.1.2 Alpha Thalassemia
5.1.3 Beta thalassemia
5.1.4 Sickle Cell Disease
5.1.5 Hb Variants Diseases
5.2 By Application - Global Hemoglobinopathies Drugs Revenue & Forecasts
5.2.1 By Application - Global Hemoglobinopathies Drugs Revenue, 2018-2023
5.2.2 By Application - Global Hemoglobinopathies Drugs Revenue, 2024-2030
5.2.3 By Application - Global Hemoglobinopathies Drugs Revenue Market Share, 2018-2030
5.3 By Application - Global Hemoglobinopathies Drugs Sales & Forecasts
5.3.1 By Application - Global Hemoglobinopathies Drugs Sales, 2018-2023
5.3.2 By Application - Global Hemoglobinopathies Drugs Sales, 2024-2030
5.3.3 By Application - Global Hemoglobinopathies Drugs Sales Market Share, 2018-2030
5.4 By Application - Global Hemoglobinopathies Drugs Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Hemoglobinopathies Drugs Market Size, 2022 & 2030
6.2 By Region - Global Hemoglobinopathies Drugs Revenue & Forecasts
6.2.1 By Region - Global Hemoglobinopathies Drugs Revenue, 2018-2023
6.2.2 By Region - Global Hemoglobinopathies Drugs Revenue, 2024-2030
6.2.3 By Region - Global Hemoglobinopathies Drugs Revenue Market Share, 2018-2030
6.3 By Region - Global Hemoglobinopathies Drugs Sales & Forecasts
6.3.1 By Region - Global Hemoglobinopathies Drugs Sales, 2018-2023
6.3.2 By Region - Global Hemoglobinopathies Drugs Sales, 2024-2030
6.3.3 By Region - Global Hemoglobinopathies Drugs Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Hemoglobinopathies Drugs Revenue, 2018-2030
6.4.2 By Country - North America Hemoglobinopathies Drugs Sales, 2018-2030
6.4.3 US Hemoglobinopathies Drugs Market Size, 2018-2030
6.4.4 Canada Hemoglobinopathies Drugs Market Size, 2018-2030
6.4.5 Mexico Hemoglobinopathies Drugs Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Hemoglobinopathies Drugs Revenue, 2018-2030
6.5.2 By Country - Europe Hemoglobinopathies Drugs Sales, 2018-2030
6.5.3 Germany Hemoglobinopathies Drugs Market Size, 2018-2030
6.5.4 France Hemoglobinopathies Drugs Market Size, 2018-2030
6.5.5 U.K. Hemoglobinopathies Drugs Market Size, 2018-2030
6.5.6 Italy Hemoglobinopathies Drugs Market Size, 2018-2030
6.5.7 Russia Hemoglobinopathies Drugs Market Size, 2018-2030
6.5.8 Nordic Countries Hemoglobinopathies Drugs Market Size, 2018-2030
6.5.9 Benelux Hemoglobinopathies Drugs Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Hemoglobinopathies Drugs Revenue, 2018-2030
6.6.2 By Region - Asia Hemoglobinopathies Drugs Sales, 2018-2030
6.6.3 China Hemoglobinopathies Drugs Market Size, 2018-2030
6.6.4 Japan Hemoglobinopathies Drugs Market Size, 2018-2030
6.6.5 South Korea Hemoglobinopathies Drugs Market Size, 2018-2030
6.6.6 Southeast Asia Hemoglobinopathies Drugs Market Size, 2018-2030
6.6.7 India Hemoglobinopathies Drugs Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Hemoglobinopathies Drugs Revenue, 2018-2030
6.7.2 By Country - South America Hemoglobinopathies Drugs Sales, 2018-2030
6.7.3 Brazil Hemoglobinopathies Drugs Market Size, 2018-2030
6.7.4 Argentina Hemoglobinopathies Drugs Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Hemoglobinopathies Drugs Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Hemoglobinopathies Drugs Sales, 2018-2030
6.8.3 Turkey Hemoglobinopathies Drugs Market Size, 2018-2030
6.8.4 Israel Hemoglobinopathies Drugs Market Size, 2018-2030
6.8.5 Saudi Arabia Hemoglobinopathies Drugs Market Size, 2018-2030
6.8.6 UAE Hemoglobinopathies Drugs Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 Gamida Cell
7.1.1 Gamida Cell Company Summary
7.1.2 Gamida Cell Business Overview
7.1.3 Gamida Cell Hemoglobinopathies Drugs Major Product Offerings
7.1.4 Gamida Cell Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Gamida Cell Key News & Latest Developments
7.2 Alnylam Pharmaceuticals
7.2.1 Alnylam Pharmaceuticals Company Summary
7.2.2 Alnylam Pharmaceuticals Business Overview
7.2.3 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Major Product Offerings
7.2.4 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Alnylam Pharmaceuticals Key News & Latest Developments
7.3 Biogen Idec
7.3.1 Biogen Idec Company Summary
7.3.2 Biogen Idec Business Overview
7.3.3 Biogen Idec Hemoglobinopathies Drugs Major Product Offerings
7.3.4 Biogen Idec Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Biogen Idec Key News & Latest Developments
7.4 Sangamo BioSciences Inc.
7.4.1 Sangamo BioSciences Inc. Company Summary
7.4.2 Sangamo BioSciences Inc. Business Overview
7.4.3 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Major Product Offerings
7.4.4 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Sangamo BioSciences Inc. Key News & Latest Developments
7.5 Genetix Pharmaceuticals/Bluebird Bio
7.5.1 Genetix Pharmaceuticals/Bluebird Bio Company Summary
7.5.2 Genetix Pharmaceuticals/Bluebird Bio Business Overview
7.5.3 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Major Product Offerings
7.5.4 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Genetix Pharmaceuticals/Bluebird Bio Key News & Latest Developments
7.6 Global Blood Therapeutics Inc.
7.6.1 Global Blood Therapeutics Inc. Company Summary
7.6.2 Global Blood Therapeutics Inc. Business Overview
7.6.3 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Major Product Offerings
7.6.4 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Global Blood Therapeutics Inc. Key News & Latest Developments
7.7 Pfizer Inc.
7.7.1 Pfizer Inc. Company Summary
7.7.2 Pfizer Inc. Business Overview
7.7.3 Pfizer Inc. Hemoglobinopathies Drugs Major Product Offerings
7.7.4 Pfizer Inc. Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Pfizer Inc. Key News & Latest Developments
7.8 Mast Therapeutics
7.8.1 Mast Therapeutics Company Summary
7.8.2 Mast Therapeutics Business Overview
7.8.3 Mast Therapeutics Hemoglobinopathies Drugs Major Product Offerings
7.8.4 Mast Therapeutics Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Mast Therapeutics Key News & Latest Developments
7.9 Emmaus Life Sciences, Inc.
7.9.1 Emmaus Life Sciences, Inc. Company Summary
7.9.2 Emmaus Life Sciences, Inc. Business Overview
7.9.3 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Major Product Offerings
7.9.4 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Emmaus Life Sciences, Inc. Key News & Latest Developments
7.10 Prolong Pharmaceuticals
7.10.1 Prolong Pharmaceuticals Company Summary
7.10.2 Prolong Pharmaceuticals Business Overview
7.10.3 Prolong Pharmaceuticals Hemoglobinopathies Drugs Major Product Offerings
7.10.4 Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Prolong Pharmaceuticals Key News & Latest Developments
7.11 Celgene Corporation
7.11.1 Celgene Corporation Company Summary
7.11.2 Celgene Corporation Hemoglobinopathies Drugs Business Overview
7.11.3 Celgene Corporation Hemoglobinopathies Drugs Major Product Offerings
7.11.4 Celgene Corporation Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Celgene Corporation Key News & Latest Developments
7.12 HemaQuest Pharmaceuticals
7.12.1 HemaQuest Pharmaceuticals Company Summary
7.12.2 HemaQuest Pharmaceuticals Hemoglobinopathies Drugs Business Overview
7.12.3 HemaQuest Pharmaceuticals Hemoglobinopathies Drugs Major Product Offerings
7.12.4 HemaQuest Pharmaceuticals Hemoglobinopathies Drugs Sales and Revenue in Global (2018-2023)
7.12.5 HemaQuest Pharmaceuticals Key News & Latest Developments
8 Global Hemoglobinopathies Drugs Production Capacity, Analysis
8.1 Global Hemoglobinopathies Drugs Production Capacity, 2018-2030
8.2 Hemoglobinopathies Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Hemoglobinopathies Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Hemoglobinopathies Drugs Supply Chain Analysis
10.1 Hemoglobinopathies Drugs Industry Value Chain
10.2 Hemoglobinopathies Drugs Upstream Market
10.3 Hemoglobinopathies Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Hemoglobinopathies Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Hemoglobinopathies Drugs in Global Market
Table 2. Top Hemoglobinopathies Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Hemoglobinopathies Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Hemoglobinopathies Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Hemoglobinopathies Drugs Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Hemoglobinopathies Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Hemoglobinopathies Drugs Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Hemoglobinopathies Drugs Product Type
Table 9. List of Global Tier 1 Hemoglobinopathies Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hemoglobinopathies Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Hemoglobinopathies Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Hemoglobinopathies Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Hemoglobinopathies Drugs Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Hemoglobinopathies Drugs Sales (K Pcs), 2018-2023
Table 15. By Type - Global Hemoglobinopathies Drugs Sales (K Pcs), 2024-2030
Table 16. By Application ? Global Hemoglobinopathies Drugs Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Hemoglobinopathies Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Hemoglobinopathies Drugs Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Hemoglobinopathies Drugs Sales (K Pcs), 2018-2023
Table 20. By Application - Global Hemoglobinopathies Drugs Sales (K Pcs), 2024-2030
Table 21. By Region ? Global Hemoglobinopathies Drugs Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Hemoglobinopathies Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Hemoglobinopathies Drugs Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Hemoglobinopathies Drugs Sales (K Pcs), 2018-2023
Table 25. By Region - Global Hemoglobinopathies Drugs Sales (K Pcs), 2024-2030
Table 26. By Country - North America Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Hemoglobinopathies Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Hemoglobinopathies Drugs Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Hemoglobinopathies Drugs Sales, (K Pcs), 2024-2030
Table 30. By Country - Europe Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Hemoglobinopathies Drugs Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Hemoglobinopathies Drugs Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Hemoglobinopathies Drugs Sales, (K Pcs), 2024-2030
Table 34. By Region - Asia Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Hemoglobinopathies Drugs Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Hemoglobinopathies Drugs Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Hemoglobinopathies Drugs Sales, (K Pcs), 2024-2030
Table 38. By Country - South America Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Hemoglobinopathies Drugs Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Hemoglobinopathies Drugs Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Hemoglobinopathies Drugs Sales, (K Pcs), 2024-2030
Table 42. By Country - Middle East & Africa Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Hemoglobinopathies Drugs Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Hemoglobinopathies Drugs Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Hemoglobinopathies Drugs Sales, (K Pcs), 2024-2030
Table 46. Gamida Cell Company Summary
Table 47. Gamida Cell Hemoglobinopathies Drugs Product Offerings
Table 48. Gamida Cell Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. Gamida Cell Key News & Latest Developments
Table 50. Alnylam Pharmaceuticals Company Summary
Table 51. Alnylam Pharmaceuticals Hemoglobinopathies Drugs Product Offerings
Table 52. Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. Alnylam Pharmaceuticals Key News & Latest Developments
Table 54. Biogen Idec Company Summary
Table 55. Biogen Idec Hemoglobinopathies Drugs Product Offerings
Table 56. Biogen Idec Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. Biogen Idec Key News & Latest Developments
Table 58. Sangamo BioSciences Inc. Company Summary
Table 59. Sangamo BioSciences Inc. Hemoglobinopathies Drugs Product Offerings
Table 60. Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. Sangamo BioSciences Inc. Key News & Latest Developments
Table 62. Genetix Pharmaceuticals/Bluebird Bio Company Summary
Table 63. Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Product Offerings
Table 64. Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. Genetix Pharmaceuticals/Bluebird Bio Key News & Latest Developments
Table 66. Global Blood Therapeutics Inc. Company Summary
Table 67. Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Product Offerings
Table 68. Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. Global Blood Therapeutics Inc. Key News & Latest Developments
Table 70. Pfizer Inc. Company Summary
Table 71. Pfizer Inc. Hemoglobinopathies Drugs Product Offerings
Table 72. Pfizer Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 73. Pfizer Inc. Key News & Latest Developments
Table 74. Mast Therapeutics Company Summary
Table 75. Mast Therapeutics Hemoglobinopathies Drugs Product Offerings
Table 76. Mast Therapeutics Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 77. Mast Therapeutics Key News & Latest Developments
Table 78. Emmaus Life Sciences, Inc. Company Summary
Table 79. Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Product Offerings
Table 80. Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 81. Emmaus Life Sciences, Inc. Key News & Latest Developments
Table 82. Prolong Pharmaceuticals Company Summary
Table 83. Prolong Pharmaceuticals Hemoglobinopathies Drugs Product Offerings
Table 84. Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 85. Prolong Pharmaceuticals Key News & Latest Developments
Table 86. Celgene Corporation Company Summary
Table 87. Celgene Corporation Hemoglobinopathies Drugs Product Offerings
Table 88. Celgene Corporation Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 89. Celgene Corporation Key News & Latest Developments
Table 90. HemaQuest Pharmaceuticals Company Summary
Table 91. HemaQuest Pharmaceuticals Hemoglobinopathies Drugs Product Offerings
Table 92. HemaQuest Pharmaceuticals Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 93. HemaQuest Pharmaceuticals Key News & Latest Developments
Table 94. Hemoglobinopathies Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 95. Global Hemoglobinopathies Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 96. Global Hemoglobinopathies Drugs Production by Region, 2018-2023 (K Pcs)
Table 97. Global Hemoglobinopathies Drugs Production by Region, 2024-2030 (K Pcs)
Table 98. Hemoglobinopathies Drugs Market Opportunities & Trends in Global Market
Table 99. Hemoglobinopathies Drugs Market Drivers in Global Market
Table 100. Hemoglobinopathies Drugs Market Restraints in Global Market
Table 101. Hemoglobinopathies Drugs Raw Materials
Table 102. Hemoglobinopathies Drugs Raw Materials Suppliers in Global Market
Table 103. Typical Hemoglobinopathies Drugs Downstream
Table 104. Hemoglobinopathies Drugs Downstream Clients in Global Market
Table 105. Hemoglobinopathies Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Hemoglobinopathies Drugs Segment by Type in 2022
Figure 2. Hemoglobinopathies Drugs Segment by Application in 2022
Figure 3. Global Hemoglobinopathies Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Hemoglobinopathies Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Hemoglobinopathies Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. Hemoglobinopathies Drugs Sales in Global Market: 2018-2030 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Hemoglobinopathies Drugs Revenue in 2022
Figure 9. By Type - Global Hemoglobinopathies Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Hemoglobinopathies Drugs Revenue Market Share, 2018-2030
Figure 11. By Type - Global Hemoglobinopathies Drugs Sales Market Share, 2018-2030
Figure 12. By Type - Global Hemoglobinopathies Drugs Price (USD/Pcs), 2018-2030
Figure 13. By Application - Global Hemoglobinopathies Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Hemoglobinopathies Drugs Revenue Market Share, 2018-2030
Figure 15. By Application - Global Hemoglobinopathies Drugs Sales Market Share, 2018-2030
Figure 16. By Application - Global Hemoglobinopathies Drugs Price (USD/Pcs), 2018-2030
Figure 17. By Region - Global Hemoglobinopathies Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Hemoglobinopathies Drugs Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Hemoglobinopathies Drugs Revenue Market Share, 2018-2030
Figure 20. By Region - Global Hemoglobinopathies Drugs Sales Market Share, 2018-2030
Figure 21. By Country - North America Hemoglobinopathies Drugs Revenue Market Share, 2018-2030
Figure 22. By Country - North America Hemoglobinopathies Drugs Sales Market Share, 2018-2030
Figure 23. US Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Hemoglobinopathies Drugs Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Hemoglobinopathies Drugs Sales Market Share, 2018-2030
Figure 28. Germany Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. France Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Hemoglobinopathies Drugs Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Hemoglobinopathies Drugs Sales Market Share, 2018-2030
Figure 37. China Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. India Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Hemoglobinopathies Drugs Revenue Market Share, 2018-2030
Figure 43. By Country - South America Hemoglobinopathies Drugs Sales Market Share, 2018-2030
Figure 44. Brazil Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Hemoglobinopathies Drugs Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Hemoglobinopathies Drugs Sales Market Share, 2018-2030
Figure 48. Turkey Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Hemoglobinopathies Drugs Revenue, (US$, Mn), 2018-2030
Figure 52. Global Hemoglobinopathies Drugs Production Capacity (K Pcs), 2018-2030
Figure 53. The Percentage of Production Hemoglobinopathies Drugs by Region, 2022 VS 2030
Figure 54. Hemoglobinopathies Drugs Industry Value Chain
Figure 55. Marketing Channels
